Wockhardt Q3 Results: Pharma Major Swings Back To Profit As Expenses Fall

On the operating side, Ebitda jumped to Rs 128 crore from Rs 37 crore, while margin expanded to 17.8% from 5.3%.

Wockhardt Ltd. plans to launch Miqnaf in the next three months. (Photo source: Company website)

Wockhardt Ltd. swung back to profit in the quarter ended December 2024, with a bottom line of Rs 14 crore, according to an exchange filing on Friday.

Also Read: Wockhardt Sees New Drugs To Fight Superbugs As Next Growth Driver

Wockhardt's share price was trading 2% higher at Rs 1,618 apiece at 2:15 p.m. on the NSE, compared to a 0.39% drop in the benchmark Nifty 50. A day prior, the stock spiked 1.5% after the results.

The stock has risen 262.05% in the last 12 months. Total traded volume so far in the day stood at 0.54 times its 30-day average. The relative strength index was at 58.81.

Also Read: Q3 Results Updates: LIC, M&M, Mazagon Dock Profit Surges; NHPC Profit Slips, Ola Electric Loss Widens

Watch LIVE TV, Get Stock Market Updates, Top Business, IPO and Latest News on NDTV Profit.
WRITTEN BY
Sai Aravindh
Sai Aravindh is a desk writer at NDTV Profit, where he covers business and ... more
GET REGULAR UPDATES